BioPharma Dive January 2, 2025
Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology sector regain its footing after a shaky year.
The biotechnology sector once again starts a new year on shaky footing.
Acquisitions of publicly traded biotech companies have slowed. An anticipated upswing in initial public offerings hasn’t materialized, and most companies that did reach Wall Street in 2024 struggled to hold their value. The prospect of Robert F. Kennedy Jr. overseeing the Department of Health...
Today's Sponsors
Today's Sponsor